introduction: spatial dose distribution around the radionuclides sources is required for optimized treatment planning in radioimmunotherapy. at present, the main source of data for cellular dosimetry is the s-values provided by mird. however, the mird s-values have been calculated based on analytical formula in which no electrons straggling is taken to account. in this study, we used geant4-dna...

Ibritumomab, an (90)Yttrium ((90)Y) labelled radioimmunoconjugate, is registered in Europe to treat follicular lymphomas. Its mode of action combines the selectivity of monoclonal antibodies with the efficiency of radiotherapy, making it a unique and useful therapeutic agent. This paper is for haemato-oncologists with a decent practice in lymphoma therapy, who have not yet used ibritumomab them...

We investigated the utility of radioimmunotherapy (RIT) in early and established cryptococcal infection in immunocompetent mice. RIT with (213)Bi-18B7 antibody completely eliminated fungus from mouse lungs and brains for early infection, while (188)Re-18B7 significantly reduced CFU in the lungs or both lungs and brains during early and established infection, respectively. The results point to t...